839 results found.
Strategic Orthopaedic-related 510(k)s issued in July 2016
Strategic orthopaedic-related 510(k)s issued in July 2016 include: 
Bioventus Launches GELSYN-3 HA for Treatment of Knee Osteoarthritis Pain
Bioventus commenced U.S. launch of GELSYN-3™ three-injection hyaluronic acid for relief of pain associat...
Vericel Reports 2Q16 Orthobiologic Revenue
Vericel posted 2Q16 Carticel revenue of US $9.0MM, -1.1% vs. 2Q15, as reported. 
Wright Medical Posts 2Q16 Revenue
Wright Medical reported 2Q16 revenue of US $170.7MM, +13.7% from 2Q15. (U.S. $121.9MM, +15.6%; ex-U.S. $48.8MM, +9%
Episurf Medical Granted EU Patent for Drilling Guide
Episurf Medical was granted an EU patent for a surgical drilling guide with functionality for depth adjustments
Smith & Nephew Posts 2Q16 Revenue
ORTHOWORLD estimates Smith & Nephew 2Q16 orthopaedic revenue of US $824.8MM, +4.3% from 2Q15. Growth is as reported.
Anika Therapeutics Posts 2Q16 Orthobiologic Revenue
Anika Therapeutics posted 2Q16 orthobiologic revenue of US $23.3MM, +20.9% vs. 2Q15, as-reported.
ConMed Reports 2Q16 Orthopaedic Revenue
ConMed posted 2Q16 arthroscopy/soft tissue revenue of US $92.7MM, -4.2% vs. 2Q15. (U.S. -5.1%, ex-U.S. -3.6%
Zimmer Biomet Reports 2Q16 Revenue
ORTHOWORLD estimates Zimmer Biomet 2Q16 orthopaedic revenue of US $1,770.5MM, +3.1% from 2Q15, as reported.
Sanofi Reports 2Q16 Synvisc Revenue
Sanofi posted 2Q16 Synvisc viscosupplementation product revenue of €109.0MM (~US $121.4MM), -6.5% from 2Q15, as-reporte...
Seikagaku Posts Quarterly Revenue
Seikagaku posted 1QFY16 revenue of ¥8.2BB (~US $80.5MM), +6.6% vs. the prior year.
MiMedx Planning U.S. Launch for Ambient Temperature Version of OrthoFlo
MiMedx is planning a U.S. launch for a next-generation lyophilized version of OrthoFlo, its amn...
Clinical Study Results: AMNIOX CLARIX FLO and CLARIX CORD in Foot and Ankle Procedures
Study results suggest that AMNIOX Medical's CLARIX®  FLO and CLARIX® CORD 1K regenerative therapies 
Wright’s Dedication to Extremities Strategies Brings Questions of What’s Next
By Carolyn LaWell Wright Medical’s divestiture of its large joint portfolio to Corin Orthopaedics officially turns Wright into the extremities company that it set out to become years ago, and leads to the question: What’s next in their M&A strategy?
Stryker Posts 2Q16 Revenue
ORTHOWORLD estimates Stryker's 2Q16 orthopaedic revenue at US $1,555.9MM, +4.0% from 2Q15. (Growth is as-reported.)
Developing New Orthopaedic Business Models: 2020 and Beyond
By Carolyn LaWell  To thrive in the healthcare environment of tomorrow, orthopaedic device companies will need to operate within a greater portion of the supply chain, assisting upstream and downstream customers in finding operational value. This will require companies...
DePuy Synthes/JNJ Posts 2Q16 Revenue
DePuy Synthes posted 2Q16 orthopaedic revenue of US $2,355MM, +1.1% vs. 2Q15. (U.S. $1,364MM, +3.3%; ex-U.S. $991MM,...
Stryker Debuts SonicAnchor Ultrasonic Soft Tissue Technology
Stryker's Foot & Ankle unit announced U.S. availability of SonicAnchor™, reportedly the only implant in the U.S. that employs
Implanet Reports 2Q16 Revenue
Implanet posted 2Q16 revenue of €2.1MM (~US $2.3MM), +22.6% vs. 2Q15, as-reported.
First U.S. Procedure with Cartiva Synthetic Cartilage Implant
The first commercial U.S. patient has received the Cartiva Synthetic Cartilage Implant following its FDA Premarket Approval
PONTiS Orthopaedics On Track to Double Sales in 2016
PONTiS Orthopaedics reported that 1H16 revenues grew >150% vs. 1H15. Performance is attributed to increasing acceptance of t...
Bioventus Extends Distribution Agreement for SUPARTZ FX Viscosupplement
Bioventus entered into an agreement with Seikagaku to continue U.S. distribution of SUP...
Cartiva Announces FDA Premarket Approval for Cartiva Synthetic Cartilage Implant
Cartiva received FDA Premarket Approval for the Synthetic Cartilage Implant to treat arthritis of the g...
1H16 M&A Recap: Big Players Make Moves
During 1H16, seven of the eight largest orthopaedic device companies confirmed or completed acquisitions or divestitures spanning nearly every orthopaedic market segment. Most notably, Stryker and Zimmer Biomet both announced three orthopaedic-related acquisitions, with Zimmer Biom...
1H16 Funding Recap: Spine Remains Dominant Market for Investments
ORTHOWORLD reported 18 funding announcements in 1H16, compared to 23 in 1H15. Similar to recent years, the spine market was the largest target for funding. Half of the announcements in 1H16 were made by companies seeking to commercialize products for spinal indications, while three more have prod...
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2018 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group